FDA Alerts
FDA expands use of Xarelto to treat, reduce recurrence of blood clots
The US Food and Drug Administration today expanded the approved use of Xarelto (rivaroxaban) to include treating deep vein thrombosis (DVT) or pulmonary embolism (PE), and to reduce the risk of recurrent DVT and PE following initial treatment.
FDA Approves Xarelto To Reduce Risk Of Blood Clots
On July 1, the U.S. Food and Drug Administration approved Xarelto ( rivaroxaban ) to reduce the risk of blood clots, deep vein thrombosis ( DVT ), and pulmonary embolism (PE) following knee or hip replacement surgery.